The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
BioVersys signs exclusive license option agreement with Shionogi for ansamycin development.
Jul 02, 2025•12 months ago
Contract Type
agreement
BaselBiotechnologyPharmaceuticalresearch
Description
BioVersys has entered into a research and exclusive license option agreement with Shionogi to develop novel ansamycin leads from its BV500 program. The agreement includes an upfront payment of $6.25 million and potential future milestones of up to 479 million francs.
Company Information
Company
BioVersys
Location
60C Hochbergerstrasse
Basel, Basel-City, Switzerland
About
BioVersys is a Swiss biopharmaceutical company focused on developing innovative treatments for antibiotic-resistant infections. The company specializes in the development of novel drugs to combat serious infectious diseases. Their BV500 program aims to advance new drug candidates into clinical trials.
BaselBiotechnologyPharmaceuticalresearch